-+ 0.00%
-+ 0.00%
-+ 0.00%

TVARDI THERAPEUTICS, - PHASE 1 STUDY OF TTI-109 SHOWS PREDICTABLE PHARMACOKINETICS AND FAVORABLE GI TOLERABILITY

Reuters·09/24/2026 12:00:31

Please log in to view news